Lymphoma Trial, Recruiting (NCT06481826)

Lymphoma Trial, Recruiting NCT06481826 Sponsor: Peking Union Medical College Hospital Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06481826 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a specific type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL), confirmed through a tissue sample test
People whose cancer has come back or did not respond to at least two previous rounds of treatment
People who have cancer that can be measured through scans or tests

Who may not be able to join:

People who are pregnant or currently breastfeeding
People who have an active infection, or a previous infection that has become active again
People who have an active autoimmune disease (where the immune system attacks the body) or a condition that weakens the immune system
People with severe organ problems, including significantly reduced heart pumping ability, poor lung function, low kidney function, or high levels of bilirubin (a substance related to liver function) (confirm with trial site for specific measurements)
People who have a close personal or financial relationship with the company running the trial, the doctor leading the trial, or the trial location

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8615201435860

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06481826

Sponsor: Peking Union Medical College Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: +8615201435860

More information: https://clinicaltrials.gov/study/NCT06481826

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a specific type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL), confirmed through a tissue sample test
People whose cancer has come back or did not respond to at least two previous rounds of treatment
People who have cancer that can be measured through scans or tests

Who may not be able to join:

People who are pregnant or currently breastfeeding
People who have an active infection, or a previous infection that has become active again
People who have an active autoimmune disease (where the immune system attacks the body) or a condition that weakens the immune system
People with severe organ problems, including significantly reduced heart pumping ability, poor lung function, low kidney function, or high levels of bilirubin (a substance related to liver function) (confirm with trial site for specific measurements)
People who have a close personal or financial relationship with the company running the trial, the doctor leading the trial, or the trial location

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peking Union Medical College Hospital

Registry

ClinicalTrials.gov

Start date

1 January 2024

Est. completion

31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov